United Therapeutics Q4 Earnings: Sky May Be The Limit For This Management Team

Edmund InghamInvesting Group LeaderFollow5ShareSavePlay(16min)CommentsSummaryUnited Therapeutics Corporation delivered strong Q4 and FY2025 results, with revenues up 10%+ and net income per share up ~14%, driving a >75% stock rally.UTHR's Tyvaso remains the dominant PAH franchise, with robust growth and new product innovations like Tresmi and ralinepag poised to reinforce market leadership.Major data catalysts in PAH (ralinepag Phase 3) and IPF (TETON-1/2) could unlock billion-dollar opportunities and further accelerate UTHR's revenue trajectory.I maintain a bullish outlook on UTHR, targeting >$5bn revenue by 2027 and >$7.5bn by 2030, though upcoming trial results present material risks.Looking for higher risk/reward options trading ideas? I offer this and much more at my exclusive investing ideas service, Haggerston BioHealth. Learn More » Дмитрий Ларичев/iStock via Getty Images Investment Overview United Therapeutics Corporation (UTHR), the Silver Spring, Maryland, headquartered pharma company with a multi-billion dollar pulmonary arterial hypertension ("PAH" a rare, chronic condition characterized by high blood pressure in the lung arteries) drug product franchise,This article was written byEdmund Ingham14.75K FollowersFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in UTHR over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.